Anna Azvolinsky, PhD

Anna Azvolinsky, PhD

Freelance Science Writer and Cancer Network Contributor.

Follow Her on Twitter

Posts by Author

How low-risk prostate cancer is managed depends more on the diagnosing physician than the patient’s disease state. Men who were diagnosed by a urologist were more likely to receive a treatment performed by the urologist and more likely to receive a therapy rather than monitoring.

The FDA approved idelalisib (Zydelig) yesterday for the treatment of relapsed chronic lymphocytic leukemia (CLL), follicular B-cell non-Hodgkin lymphoma (FL), and small lymphocytic lymphoma (SLL).

An annual screening for breast cancer using a combination of MRI and mammography could be an effective program for high-risk women, particularly those who are known BRCA mutation carriers.

A phase II study demonstrated that cetuximab plus docetaxel-based chemoradiotherapy postoperatively in patients with high-risk squamous cell carcinoma of the head and neck led to improved disease-free and overall survival.

Age is a prognostic factor for both overall survival and progression-free survival among patients diagnosed with metastatic colorectal cancer, according to the results of a study.

Men who underwent a vasectomy had a modest increase in the incidence of prostate cancer—and particularly lethal prostate cancer.

A new study provides evidence that a daily aspirin may reduce the risk of developing pancreatic cancer.

The combination of four imaging techniques together results in the ability to better differentiate between benign and malignant breast tumors, which may lead to fewer unnecessary breast biopsies.

Women who consume increased amounts of red meat have a higher risk of breast cancer compared with those who have a protein intake consisting largely of non–red meat such as poultry, fish, and legumes.

The CALGB 369901 trial examined how frailty and older age influence the use of adjuvant hormonal therapy for breast cancer and found that while frailty can deter the start of therapy, frail patients who had started on a regimen were not much more likely to discontinue their treatment early.


By clicking Accept, you agree to become a member of the UBM Medica Community.